The chances of surviving cardiac arrest in the hospital have improved nearly 12 percent in the last decade, possibly because of the introduction of new treatment approaches and guidelines, including therapeutic hypothermia. “Post Cardiac-Arrest Mortality Is Declining: A Study of the U.S. National Inpatient Sample 2001–2009,” which was published in Circulation, adds that the lowered mortality rate for cardiac arrest is a fact that sneaked up on us.

Researchers used the 2001–2009 U.S. National Inpatient Sample (NIS), a national hospital discharge database, to determine the mortality rates. In that time, nearly 1.2 million people were hospitalized with the condition. The in-hospital mortality rate decreased from 69.6 percent to 57.8 percent. “The mortality rate declined across all analyzed subgroups, including gender, age, race, and stratification by comorbidity,” the study states.

Researchers stress that the numbers are for people who survive long enough to make it to the hospital. Many aren’t so fortunate. The study cites new guidelines by the American Heart Association that stress CPR without mouth contact and easy-to-use automated external defibrillators for shockable arrhythmias. They also cite randomized trials that “showed that induced hypothermia reduces mortality and improves neurologic outcomes in patients with out-of-hospital ventricular fibrillation cardiac arrest.” The idea is to cool the body by IV saline, cooling blankets, or ice packs. That helps protect the brain until the patients can be slowly re-warmed.

Alejandro Rabinstein, MD, of the Mayo Clinic, lead researcher, tells Managed Care, “Our analysis … cannot discriminate between the various factors that may have contributed to the decline (better access to defibrillators, early coronary interventions, and therapeutic hypothermia, among others), thus providing indirect data to justify their application and expense. The improvement in mortality correlated with the gradual implementation of therapeutic hypothermia, but we cannot prove that this treatment was a major determinant for the improved outcomes.”

Still, changes in the care of these patients, rather than a change in the population itself, probably led to this decline in mortality. “The improvement in mortality was not explained by a change in the demographics or comorbidities of the patients with cardiac arrest,” says Rabinstein. “In fact, mortality diminished in recent years although resuscitated patients had more comorbidities at baseline. This is a reason not to give up on these patients before attempting aggressive resuscitation measures.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.